Acutaas Chemicals Ltd

- Ami Organics has taken Rs. 119 crores of debt to fund the Ankleshwar facility capex. - The total capex outlay for the Ankleshwar unit was revised upwards from Rs. 190 crores to Rs. 310 crores, involving additional machinery and infrastructure for a CDMO contract. - The company plans to fund capex through a mix of internal accruals and debt; no mention of fresh equity fundraising was made. - Finance cost for Q3 was Rs. 25 million and is expected to be similar or slightly higher next quarter due to additional capex borrowings. - The overall debt-to-equity ratio after the recent debt is around 63% debt and 37% equity, indicating no immediate plans for equity dilution. - No explicit future plans for new fundraising (debt or equity) beyond these were discussed in the call.

- Total capex outlay for Ankleshwar unit revised from Rs. 190 crores to Rs. 310 crores due to additional machinery for CDMO contract and allied infrastructure. - Rs. 119 crores debt taken to fund this capex, with overall funding through a mix of internal accruals and debt. - Ankleshwar facility upgradation ongoing and expected to complete soon. - Rs. 300 crores capex planned, mostly for electrolyte business, but deployment will take some time. - Ankleshwar facility expected to have a turnover of 3-3.5x the asset value post-upgrade. - No capital infusion planned currently for Baba Fine Chemicals acquisition; it is an established business. - Capacity expansion planned for electrolyte additives: from current 500 metric tons each to an additional 2,000 metric tons each. - Electrolyte CDMO business is CAPEX intensive with standard multi-year ramp-up timeline.

- Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing erosion. - For FY25, revenue growth is expected between 17-22%, driven by ramp-up in Fermion contract, new electrolyte products, and other projects. - Volume growth has been strong at 25% year-on-year, indicating robust business traction despite pricing pressures. - The company plans to achieve Rs. 1,000 crore revenue target by mid-FY26. - Electrolyte additives supply has commenced commercially with long-term contracts signed; capacity expansion planned from 500 MT to 2,000 MT. - New Ankleshwar plant inauguration and partnerships (e.g., with Fermion) expected to boost higher-value advanced intermediates production. - Expansion in Specialty Chemical and Pharma Intermediate segments with product ramp-ups expected from Q1 FY25. - Rs. 300 crore CAPEX underway (e.g., for electrolyte and Ankleshwar facility upgrades) to enable future growth.

- Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing pressures. - FY25 revenue growth is expected between 17-22%, aided by ramp-up in Fermion contract and new electrolyte projects. - EBITDA margin in Q3 FY24 was 15.9%, with a target to increase to 18-20% in the next quarter, and ultimately return towards 23% margin level. - Higher margins are expected due to stabilization of raw material prices and improved product mix. - EPS and PAT margins were impacted this quarter by lower EBITDA margin, higher depreciation, and finance costs. - CAPEX investments (Rs. 300 crores) in Ankleshwar facility and electrolyte business expected to drive long-term growth. - Volume growth remains strong at 25% YoY, supporting revenue and margin expansion over the medium term. - Management remains confident about maintaining quality growth and margin recovery in upcoming quarters.

- Ami Organics has firm orders in hand and has already moved into production, indicating a healthy current order book (Page 11). - The company is actively negotiating and in discussions with other pharmaceutical customers for additional contracts, including a 66% capacity facility (Page 15). - The Ankleshwar plant has contracts including a significant agreement with Fermion for advanced pharmaceutical intermediates, expected to ramp up gradually through FY25 (Page 15, 20). - A Rs. 300 crore toll manufacturing opportunity is targeted to be finalized and operational in FY25 (Page 15). - The management expects revenue growth and capacity utilization to improve as these orders ramp up, aiming for Rs. 1,000 crore revenue by mid-FY26 (Page 20).